



GE HealthCare



Stem Cell Research

Updated January 2024

GE HealthCare's Technology & Innovation Center performs a variety of basic scientific research. Our portfolio of research explores disease mechanisms including neurodegeneration and cancer, biomarker discovery and novel diagnostic technologies, as well as the development and delivery of novel therapeutics.

GE HealthCare has ongoing and planned research that may utilize adult-derived stem cells including induced pluripotent stem cells (iPS), mesenchymal stem cells and hematopoietic stem cells. Our research

may include use of the fetal cell line HEK 293 for transfection and for production of recombinant protein, monoclonal antibodies, and viral vectors using standard, approved laboratory practices. Beyond that, GE HealthCare has no current or planned research activities involving stem cells of embryonic or fetal origin.

We conduct all our research, including involving stem cells, in accordance with applicable laws and seek to align with good industry practice and other relevant international guidelines.